The relationship between obesity, cardiometabolic disorders and disease activity in psoriatic arthritis patients: data from the Russian register
- 作者: Korsakova Y.1, Korotaeva T.1, Loginova E.1, Gubar E.1, Vasilenko E.2, Vasilenko A.3, Kuznetsova N.4, Patrikeeva I.5, Nasonov E.1,6
-
隶属关系:
- Nasonova Research Institute of Rheumatology
- Mechnikov North-Western State Medical University
- Novgorod Regional Clinical Hospital
- City Clinical Hospital №40
- Regional Clinical Hospital №1
- Sechenov First Moscow State Medical University (Sechenov University)
- 期: 卷 93, 编号 5 (2021)
- 页面: 573–580
- 栏目: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/71511
- DOI: https://doi.org/10.26442/00403660.2021.05.200789
- ID: 71511
如何引用文章
全文:
详细
Aim. To study the relationship between obesity, cardiometabolic disorders and disease activity in patients with psoriatic arthritis (PsA) in real practice.
Materials and methods. The Russian register included 614 PsA patients [female – 331 (54%)/283 (46%)]. Average age – 45.2±0.52 years, PsA duration – 5.7±0.27 years, psoriasis – 15.71±0.56 years. Patients underwent examination, body mass index (BMI), PsA activity according to DAPSA, cDAPSA, analysis of concomitant diseases were assessed. The patients were divided into 3 groups depending on BMI (kg/m2): normal <25 (group 1), increased – 25–30 (group 2), obesity >30 (group 3).
Results. The average BMI was 27.7±0.23 kg/m2, normal BMI – in 213 (34.7%), increased – in 214 (34.8%) and obesity – in 187 (30.5%). Concomitant diseases – in 297 (48%). In group 3, arterial hypertension was observed significantly more often than in groups 1 and 2 (p<0.0001); more often than in group 2 – diabetes mellitus (p<0.0001), metabolic syndrome (p<0.0001); more often than in group 1 – ischemic heart disease (p=0.026). PsA activity at Baseline, after 6/12 months was significantly higher in group 3 (p<0.031). In obese patients, the chance of a decrease in disease activity to a moderate/low level and remission during therapy for 6/12 months is 2.484 times lower than in group 1, and 2.346 times lower than in group 2: odds ratio 2.346 (95% сonfidence interval 1.07–5.143) and 2.484 (95% сonfidence interval 1.135–5.439), respectively.
Conclusion. In the majority (65.3%) of PsA patients, BMI exceeded the norm. Obesity is associated with a high incidence of cardiometabolic disorders, with higher PsA activity and lower treatment efficacy.
作者简介
Yuliia Korsakova
Nasonova Research Institute of Rheumatology
编辑信件的主要联系方式.
Email: yulkorsakova@bk.ru
ORCID iD: 0000-0001-5968-2403
канд. мед. наук, ст. науч. сотр. лаб. спондилоартритов и псориатического артрита
俄罗斯联邦, MoscowTatiana Korotaeva
Nasonova Research Institute of Rheumatology
Email: yulkorsakova@bk.ru
ORCID iD: 0000-0003-0579-1131
д-р мед. наук, зав. лаб. спондилоартритов и псориатического артрита
俄罗斯联邦, MoscowElena Loginova
Nasonova Research Institute of Rheumatology
Email: yulkorsakova@bk.ru
ORCID iD: 0000-0001-6875-4552
канд. мед. наук, ст. науч. сотр. лаб. спондилоартритов и псориатического артрита
俄罗斯联邦, MoscowElena Gubar
Nasonova Research Institute of Rheumatology
Email: yulkorsakova@bk.ru
ORCID iD: 0000-0001-5015-7143
канд. мед. наук, науч. сотр. лаб. спондилоартритов и псориатического артрита
俄罗斯联邦, MoscowElizaveta Vasilenko
Mechnikov North-Western State Medical University
Email: yulkorsakova@bk.ru
ORCID iD: 0000-0003-2153-5429
ассистент каф. терапии, ревматологии, экспертизы временной нетрудоспособности и качества медицинской помощи им. Э.Э. Эйхвальда
俄罗斯联邦, Saint PetersburgAleksei Vasilenko
Novgorod Regional Clinical Hospital
Email: yulkorsakova@bk.ru
ORCID iD: 0000-0002-5486-2576
зав. ревматологическим отд. ГОБУЗ НОКБ
俄罗斯联邦, Veliky NovgorodNatalia Kuznetsova
City Clinical Hospital №40
Email: yulkorsakova@bk.ru
ORCID iD: 0000-0002-4972-7716
канд. мед. наук, врач-ревматолог консультативно-диагностической поликлиники ГАУЗ СО «ГКБ №40»
俄罗斯联邦, EkaterinburgIrina Patrikeeva
Regional Clinical Hospital №1
Email: yulkorsakova@bk.ru
ORCID iD: 0000-0003-0530-0080
зав. ревматологическим отд. ГБУЗ ТО «ОКБ №1», гл. специалист-ревматолог Департамента здравоохранения Тюменской области
俄罗斯联邦, TyumenEvgeny Nasonov
Nasonova Research Institute of Rheumatology; Sechenov First Moscow State Medical University (Sechenov University)
Email: yulkorsakova@bk.ru
ORCID iD: 0000-0002-1598-8360
акад. РАН, д-р мед. наук, проф., науч. рук. ФГБНУ «НИИ ревматологии им. В.А. Насоновой», проф. ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова»
俄罗斯联邦, Moscow; Moscow参考
- Noviani M, Feletar M, Nash P, et al. Choosing the right treatment for patients with psoriatic arthritis. Ther Adv Musculoskel Dis. 2020;12:1-17. doi: 10.1177/1759720X20962623
- Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74(2):326-32. doi: 10.1136/annrheumdis-2014-205675
- Husni ME, Mease PJ. Managing comorbid disease in patients with psoriatic arthritis. Curr Rheumatol Rep. 2010;12(4):281-7. doi: 10.1007/s11926-010-0112-3
- Bengtsson K, Forsblad-d’Elia H, Lie E, et al. Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. Arthritis Res Ther. 2017;19:102. doi: 10.1186/s13075-017-1315-z
- Eder L, Thavaneswaran A, Chandran V, et al. Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis. Ann Rheum Dis. 2015;74:1830-5. doi: 10.1136/annrheumdis-2014-205267
- Bhole VM, Choi HK, Burns LC, et al. Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (Oxford). 2012;51:552-6. doi: 10.1093/rheumatology/ker349
- Bostoen J, Van Praet L, Brochez L, et al. A cross-sectional study on the prevalence of metabolic syndrome in psoriasis compared to psoriatic arthritis. J Eur Acad Dermatol Venereol. 2014;28:507-11. doi: 10.1111/jdv.12071
- Labitigan M, Bahče-Altuntas A, Kremer JM, et al. Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66:600-7. doi: 10.1002/acr.22185
- Haroon M, Gallagher P, Heffernan E, FitzGerald O. High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. J Rheumatol. 2014;41:1357-65. doi: 10.3899/jrheum.140021
- Eder L, Abji F, Rosen CF, et al. The association between obesity and clinical features of psoriatic arthritis: a case-control study. J Rheumatol. 2017;44:437-43. doi: 10.3899/jrheum.160532
- Landgren AJ, Bilberg A, Eliasson B, et al. Cardiovascular risk factors are highly overrepresented in Swedish patients with psoriatic arthritis compared with the general population. Scand J Rheumatol. 2020;49(3):195-9. doi: 10.1080/03009742.2019.1672783
- Nissen CB, Hørslev-Petersen K, Primdahl J. Cardiovascular risk profiles in a hospital-based population of patients with psoriatic arthritis and ankylosing spondylitis: a cross-sectional study. Rheumatol Int. 2017;37(1):113-20. doi: 10.1007/s00296-016-3614-0
- Hellgren K, Dreyer L, Arkema EV, et al. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO register. Ann Rheum Dis. 2017;76(1):105-11. doi: 10.1136/annrheumdis-2016-209270
- Taylor WJ, Gladman DD, Helliwell PS, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665-73. doi: 10.1002/art.21972
- Schoels MM, Aletaha D, Alasti F, et al. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75(5):811-8. doi: 10.1136/annrheumdis-2015-207507
- Aletaha D, Alasti F, Smolen JS. Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression. Ann Rheum Dis. 2017;76(2):418-21. doi: 10.1136/annrheumdis-2016-209511
- Smolen JS, Schols M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018;77:3-17. doi: 10.1136/annrheumdis-2017-211734
- Horn EJ, Fox KM, Patel V, et al. Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol. 2007;57(6):963-71. doi: 10.1016/j.jaad.2007.07.023
- Fredriksson T, Pettersson U. Severe psoriasis oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44. doi: 10.1159/000250839
- Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co‐morbid conditions. J Invest Dermatol. 2010;130:1785-96. doi: 10.1038/jid.2010.103
- Grozdev I, Korman N, Tsankov N. Psoriasis as a systemic disease. Clin Dermatol. 2014;32:343-50. doi: 10.1016/j.clindermatol.2013.11.001
- Boehncke WH. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol. 2018;9:579. doi: 10.3389/fimmu.2018.00579
- Krueger JG, Brunner PM. Interleukin‐17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities. Exp Dermatol. 2018;27:115-23. doi: 10.1111/exd.13467
- Prussick RB, Miele L. Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden? Br J Dermatol. 2018;179:16-29. doi: 10.1111/bjd.16239
- Gisondi P, Del Giglio M, Girolomoni G. Considerations for systemic treatment of psoriasis in obese patients. Am J Clin Dermatol. 2016;17:609-15. doi: 10.1007/s40257-016-0211-7
- Danielsen K, Wilsgaard T, Olsen AO, et al. Elevated odds of metabolic syndrome in psoriasis: a population‐based study of age and sex differences. Br J Dermatol. 2015;172:419-27. doi: 10.1111/bjd.13288
- Takahashi H, Iizuka H. Psoriasis and metabolic syndrome. J Dermatol. 2012;39:212-8. doi: 10.1111/j.1346-8138.2011.01408.x
- Carrascosa JM, Rocamora V, Fernandez‐Torres RM, et al. Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications. Actas Dermosifiliogr. 2014;105:31-44. doi: 10.1016/j.ad.2012.08.003
- Bluher M. Adipose tissue inflammation: a cause or consequence of obesity‐related insulin resistance? Clin Sci. 2016;130:1603-14. doi: 10.1038/ncomms11378
- Ali M, Girgis S, Hassan A, et al. Inflammation and coronary artery disease: from pathophysiology to Canakinumab Anti‐Inflammatory Thrombosis Outcomes Study (CANTOS). Coron Artery Dis. 2018;29:429-37. doi: 10.1097/MCA.0000000000000625
- Shoelson SE, Goldfine AB. Getting away from glucose: fanning the flames of obesity‐induced inflammation. Nat Med. 2009;15:373-4. doi: 10.1038/nm0409-373
- Xu X, Su L, Gao Y, Ding Y. The prevalence of nonalcoholic fatty liver disease and related metabolic comorbidities was associated with age at onset of moderate to severe plaque psoriasis: a cross‐sectional study. PLoS ONE. 2017;12:e0169952. doi: 10.1371/journal.pone.0169952
- Srinivas S, Nagendra S, Goudappala, Kashinath RT. Alterations in plasma lipid profile and cardiovascular risk indicators in clinically sub-grouped psoriasis. Int J Res Dermatol. 2019;5(2):295-9. doi: 10.18203/issn.2455-4529.IntJResDermatol20190429
- Amer M, Galal A, Amer A. Psoriasis Severity is Affected by T the Lipid Profile in Egyptian Patients. Gynecol Obstet (Sunnyvale). 2015;5(12):1-3. doi: 10.4172/2161-0932.1000346
- Azevedo VF, Buiar P. Risk factors and predictors of psoriatic arthritis in patients with psoriasis. An Bras Dermatol. 2013;88(2):233-6. doi: 10.1590/S0365-05962013000200008
- Li W, Han J, Qureshi AA. Smoking and risk of incident psoriatic arthritis in US women. Ann Rheum Dis. 2012;71(6):804-8. doi: 10.1136/annrheumdis-2011-200416
- Lihi Eder L, Haddad A, Rosen CF, et al. The Incidence and Risk Factors for Psoriatic Arthritis in Patients With Psoriasis: A Prospective Cohort Study. Arthritis Rheumatol. 2016;68(4):915-23. doi: 10.1002/art.39494
- Kimball AB, Gladman DD, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008;58:1031-42. doi: 10.1016/j.jaad.2008.01.006
- Vena GA, Vestita M, Cassano N. Psoriasis and cardiovascular disease. Dermatol Ther. 2010;23:144-51. doi: 10.1111/j.1529-8019.2010.01308.x
- Prodanovich S, Kirsner R, Kravetz J, et al. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol. 2009;145:700-3.doi: 10.1001/archdermatol.2009.94
- Tobin AM, Veale DJ, Fitzgerald O, et al. Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. J Rheumatol. 2010;37:1386-94. doi: 10.3899/jrheum.090822
- Eder L, Zisman D, Barzilai M, et al. Subclinical atherosclerosis in psoriatic arthritis: a case‐control study. J Rheumatol. 2008;35:877-82. PMID: 18381785
- Kay L, Myers A, Walker D. Effects of inflammatory arthritis on quality of life in patients with psoriasis [letter]. Arch Dermatol. 2003;139:1655. doi: 10.1001/archderm.139.12.1655-a
- Ciocon DH, Horn EJ, Kimball AB. Quality of life and treatment satisfaction among patients with psoriasis and psoriatic arthritis and patients with psoriasis only: results of the 2005 Spring US National Psoriasis Foundation Survey. Am J Clin Dermatol. 2008;9:111-7. doi: 10.2165/00128071-200809020-00004
- Christophers E, Barker JN, Griffiths CE, et al. The risk of psoriasis arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol. 2010;24:548-54. doi: 10.1111/j.1468-3083.2009.03463.x
- Husted J, Thavaneswaran A, Chandran V, et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: A comparison with patients with psoriasis. Arthritis Care Res. 2011;63(12):1729-35. doi: 10.1002/acr.20627
- Erden A, Canpolat U, Uyaroğlu OA, et al. Change of subclinical atherosclerosis after five years anti-TNF treatments in psoriatic arthritis. Ann Rheum Dis. 2019;78(Suppl. 2):1269. doi: 10.1136/annrheumdis-2019-eular.6044
- Di Minno MN, Peluso R, Iervolino S, et al. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor alpha blockers. Ann Rheum Dis. 2014;73(6):1157-62. doi: 10.1136/annrheumdis-2012-202812
- Klingberg E, Bilberg A, Björkman S, et al. Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study. Arthritis Res Ther. 2019;21:17. doi: 10.1186/s13075-019-1810-5
- Abou-Raya A, Abou-Raya S, Helmii M. Effect of Exercise and Dietary Weight Loss on Symptoms and Systemic Inflammation in Obese Adults with Psoriatic Arthritis: Randomized Controlled Trial. Ann Rheum Dis. 2014;73(Suppl. 2):89-90. doi: 10.1136/annrheumdis-2014-eular.2760.
- Giles JT, Ogdie A, Gomez Reino JJ, et al. Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis. RMD Open. 2021;7:e001486. doi: 10.1136/rmdopen-2020-001486.